Public Meeting on Nanotechnology Materials in FDA-Regulated Products October 10, 2006. Scott McNeil, Ph.D. email@example.com http://ncl.cancer.gov. Preclinical Characterization of Nanoparticles. Cancer Nanotechnology Program.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
in FDA-Regulated Products
October 10, 2006
Scott McNeil, Ph.D.
Preclinical Characterization of Nanoparticles
NCL Concept of Operations:
NCL is a formal collaboration among NCI, FDA and NIST
Same parameters – different/additional characterization methods
G6-NH2Influence of Surface Chemistry/Charge
LLC-PK1 24 hr Cytotoxicity
MTT Viability Assay
NCL is working with FDA to identify parameters that contribute to biocompatibility and toxicity.
Characterization should be interdisciplinary, and conducted under biologically relevant conditions
Scott E. McNeil firstname.lastname@example.org
(301) 846-6939 http://ncl.cancer.gov